Weight Loss Research Peptides

11 research peptides demonstrate weight loss properties. This collection covers their mechanisms, evidence base, and research applications.

Exenatide is a 39-amino-acid GLP-1 receptor agonist (MW ~4186.6 g/mol) derived from exendin-4, a peptide identified in the saliva of the Gila monster (Heloderma suspectum). As the first GLP-1 receptor agonist to receive FDA approval, Exenatide was authorized in April 2005 as Byetta for type 2 diabetes, followed by Bydureon in January 2012 as a once-weekly formulation. With approximately 53% sequence homology to human GLP-1, it demonstrates resistance to DPP-4 degradation, allowing for sustained activity. Research indicates that Exenatide enhances glucose-dependent insulin secretion and suppresses glucagon levels, contributing to reduced appetite and slower gastric emptying. The immediate-release formulation has a half-life of around 2.4 hours, while the extended-release formulation employs poly(D,L-lactide-co-glycolide) microspheres for prolonged release over a week. The primary elimination route is renal, through glomerular filtration and subsequent proteolytic degradation.

Dulaglutide is a fusion protein (MW ~59,670 g/mol) that combines a GLP-1 analog with a modified human IgG4 Fc fragment, allowing for a prolonged half-life of approximately 5 days. This extended duration supports once-weekly dosing, making it convenient for patients. The GLP-1 analog within Dulaglutide retains 90% homology to native GLP-1 and includes modifications to resist DPP-4 degradation, enhancing its therapeutic profile. Studies have shown that Dulaglutide activates GLP-1 receptors, promoting glucose-dependent insulin secretion, inhibiting glucagon release, and delaying gastric emptying, all of which contribute to weight loss. The Fc fragment facilitates reduced clearance via FcRn-mediated recycling, further extending its action. Research indicates that Dulaglutide is primarily metabolized through general protein catabolism, with its efficacy demonstrated in various clinical trials for type 2 diabetes management.

Pramlintide, known by its brand name Symlin, is a synthetic analog of the 37-amino-acid pancreatic hormone amylin (MW ~3949.4 g/mol). It features three proline substitutions that prevent the amyloid aggregation characteristic of native human amylin, rendering it suitable for therapeutic use. Research indicates that Pramlintide effectively mimics the physiological actions of amylin, which include slowing gastric emptying, suppressing postprandial glucagon secretion, and promoting satiety through central nervous system pathways. These actions are particularly beneficial for individuals with diabetes, who often experience dysregulated glucagon levels. The half-life of Pramlintide is approximately 48 minutes, and it is primarily eliminated by renal processes. Clinical studies have demonstrated its potential to contribute to weight loss, particularly in conjunction with insulin therapy, highlighting its multifaceted role in metabolic regulation.

Setmelanotide, marketed as Imcivree, is an 8-amino-acid cyclic peptide (MW ~1117.3 g/mol) that acts as a selective agonist for the melanocortin 4 receptor (MC4R). It received FDA approval in June 2022 for the treatment of Bardet-Biedl syndrome (BBS), a genetic disorder that disrupts the leptin-melanocortin signaling pathway. Research suggests that Setmelanotide restores MC4R signaling, which is crucial for appetite regulation and energy expenditure. In normal physiology, leptin activates POMC neurons, leading to the production of alpha-MSH, which then activates MC4R to suppress appetite and promote energy expenditure. In patients with defects in this pathway, Setmelanotide bypasses the upstream dysfunction by directly activating MC4R, thus addressing severe hyperphagia and obesity. The peptide exhibits high affinity for MC4R (EC50 ~0.27 nM) and has a half-life of approximately 11 hours, with metabolism occurring through proteolysis and renal clearance.

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist (MW 4,563.06 g/mol) that has shown promise in clinical trials for weight management and glycemic control. Co-developed by Innovent Biologics and Eli Lilly, it combines the appetite-suppressing and glucose-lowering effects of GLP-1 with the energy expenditure-enhancing effects of glucagon. Research indicates that Mazdutide is designed for once-weekly administration, leveraging fatty acid acylation to extend its half-life. This dual action aims to provide a synergistic approach to weight management, as GLP-1 receptor activation promotes insulin secretion and reduces appetite, while glucagon receptor activation stimulates hepatic lipid oxidation and increases energy expenditure. Mazdutide has received approval from China's NMPA in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes, marking a significant advancement in the therapeutic landscape for obesity and metabolic disorders.

Pemvidutide (ALT-801) is an innovative dual GLP-1/glucagon receptor agonist under development by Altimmune, aimed at addressing obesity and nonalcoholic steatohepatitis (NASH/MASH). This peptide is designed for once-weekly administration, leveraging the appetite-suppressing effects of GLP-1 alongside the energy-enhancing and hepatic fat-reducing properties of glucagon. Currently, Pemvidutide is in Phase I–II clinical trials, with Phase III studies anticipated to commence soon.

Mechanism: Pemvidutide's dual action involves the activation of both GLP-1 and glucagon receptors. The GLP-1 receptor activation is associated with decreased appetite, increased satiety, and improved insulin secretion in a glucose-dependent manner. Conversely, glucagon receptor activation promotes hepatic lipid oxidation, boosts resting energy expenditure, and aids in reducing hepatic fat accumulation. This dual agonism presents a multifaceted approach to weight management and metabolic regulation.

Cotadutide (MEDI0382) is another dual GLP-1/glucagon receptor agonist, developed by AstraZeneca, originally emerging from MedImmune. Designed for once-daily injection, Cotadutide aims to synergize GLP-1 mediated glucose control and appetite suppression with glucagon's potential to enhance energy expenditure and promote hepatic fat oxidation. While Phase II trials have been completed in populations with type 2 diabetes, obesity, and NASH/MASH, the future of Cotadutide remains uncertain due to mixed results and shifting development priorities within AstraZeneca.

Mechanism: This synthetic peptide operates through a balanced activation of GLP-1 and glucagon receptors, with a designed activity ratio of approximately 5:1 in favor of GLP-1. The GLP-1 component enhances insulin secretion, delays gastric emptying, and suppresses glucagon, while the glucagon component stimulates fatty acid oxidation and promotes ketogenesis, contributing to overall metabolic homeostasis.

Danuglipron (PF-06882961) is a small-molecule, non-peptide oral GLP-1 receptor agonist developed by Pfizer. Although it is included in this discussion for comparison with peptide-based GLP-1 agonists, it is important to note that Danuglipron is not a peptide. Currently in Phase III development, it targets both type 2 diabetes and obesity. Initially evaluated as a twice-daily formulation, the development shifted to a once-daily modified-release version due to high discontinuation rates associated with gastrointestinal side effects in the earlier regimen.

Mechanism: Danuglipron functions as a full agonist of the GLP-1 receptor, binding to a unique site distinct from the peptide binding site. This small molecule promotes the production of cAMP, stimulating glucose-dependent insulin secretion, suppressing glucagon levels, and reducing appetite. Unlike peptide GLP-1 agonists, Danuglipron does not necessitate fasting conditions for effective absorption, thus potentially enhancing patient adherence.

Orforglipron (LY3502970) is another non-peptide small-molecule GLP-1 receptor agonist being developed by Eli Lilly. Similar to Danuglipron, it is included here for comparative purposes regarding peptide-based GLP-1 agonists. Orforglipron is currently undergoing Phase III trials (ATTAIN trial program) for the treatment of type 2 diabetes and obesity. Its once-daily dosing regimen, which does not require food restrictions, may offer enhanced convenience over traditional oral GLP-1 therapies.

Mechanism: Acting as a full agonist at the GLP-1 receptor, Orforglipron engages the same downstream signaling pathways as peptide GLP-1 agonists, facilitating glucose-dependent insulin secretion and appetite suppression. This small-molecule compound is designed to be orally bioavailable without the need for absorption enhancers, which may improve patient compliance and therapeutic outcomes.

Amycretin represents a novel approach as a first-in-class unimolecular peptide co-agonist developed by Novo Nordisk. This compound uniquely activates both GLP-1 and amylin receptors from a single molecular framework, positioning it as a promising candidate for obesity treatment, primarily in oral tablet form. Phase 3 trials for Amycretin are projected to commence in 2026, reflecting a commitment to advancing its therapeutic potential.

Mechanism: By engaging both GLP-1 and amylin receptors, Amycretin facilitates a multifaceted mechanism of action. The GLP-1 receptor activation mimics the effects seen with established GLP-1 agonists, enhancing insulin secretion and promoting satiety. Concurrently, the amylin receptor activation contributes to appetite suppression and further delays gastric emptying, offering a complementary strategy to manage body weight and metabolic health.

GLP-1 (Glucagon-Like Peptide-1) is an endogenous incretin hormone composed of 30 amino acids, secreted by intestinal L-cells in response to nutrient intake. It plays a pivotal role in the mechanism of several approved GLP-1 receptor agonist medications, including semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and liraglutide (Saxenda). Due to a short half-life of only 2-3 minutes caused by rapid degradation by DPP-4 enzymes, native GLP-1 has limited therapeutic utility; thus, engineered analogs with extended half-lives have been developed, marking a significant advancement in the treatment of diabetes and obesity.

Mechanism: GLP-1 interacts with the GLP-1 receptor (GLP-1R), a class B G-protein coupled receptor located in various tissues, including pancreatic beta cells and the central nervous system. Its activation promotes glucose-dependent insulin secretion, suppresses glucagon release, and delays gastric emptying, while also modulating appetite through central signaling pathways. The rapid degradation of native GLP-1 underscores the importance of developing stable analogs to harness its therapeutic potential effectively.